Literature DB >> 17059936

Temporary coronary artery occlusion during off-pump coronary artery bypass grafting with the new poloxamer P407 does not cause endothelial dysfunction in epicardial coronary arteries.

Olivier Bouchot1, Marie-Claude Aubin, Michel Carrier, William E Cohn, Louis P Perrault.   

Abstract

OBJECTIVE: The aim of this study was to assess the efficacy of the novel reversible thermosensitive gel poloxamer 407 for occlusion of the coronary vessel necessary for minimally invasive operations and its effects on coronary endothelium.
METHODS: Domestic swine were submitted to occlusion of the left anterior descending or right coronary artery using the poloxamer. The left and right internal thoracic arteries were used as grafts to perform coronary artery bypasses. Animals were humanely killed after 3 hours of perfusion (acute; n = 8) or 3 days (subacute; n = 6). The vascular reactivity of coronary artery was evaluated in response to serotonin and bradykinin. Histologic studies were performed to analyze cardiomyocyte necrosis and endothelial coverage.
RESULTS: The gel led to an occlusion of 7.8 +/- 2.2 minutes. Concentration-response curves of occluded coronary segments showed no difference of endothelium-dependent relaxations in both operated groups (P < .05 vs control). Histologic studies demonstrated the absence of cardiomyocyte necrosis after coronary artery occlusion in the acute group; a small infarct zone was detected in 1 animal in the subacute group, resulting from an occlusion of the first diagonal branch. The endothelial layer coverage was preserved in both groups.
CONCLUSION: The poloxamer 407 represents a promising technique for obtaining hemostasis at the site of anastomosis during construction of bypasses during beating heart coronary artery surgery, without damage to the endothelium or ischemic consequence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059936     DOI: 10.1016/j.jtcvs.2006.04.028

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  LeGoo polymer injection into hydatid cyst would eliminate intraoperative spillage of scolices.

Authors:  Fadhil Al-Amran; Hayder M Abdulnabi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-02-16

2.  Temporary targeted hemostasis to facilitate bloodless partial nephrectomy.

Authors:  Niall J Harty; Alireza Moinzadeh; Sebastian Flacke; Jeffrey Pettit; James A Benn; John A Libertino; Peter N Madras
Journal:  Urology       Date:  2011-12       Impact factor: 2.649

3.  Temporary targeted renal blood flow interruption using a reverse thermosensitive polymer to facilitate bloodless partial nephrectomy: a swine survival study.

Authors:  Niall J Harty; Daniel H Laskey; Alireza Moinzadeh; Sebastian Flacke; James A Benn; Rosanna Villani; Aarti Kalra; John A Libertino; Peter N Madras
Journal:  BJU Int       Date:  2012-03-15       Impact factor: 5.588

4.  Endovascular temporary vessel occlusion with a reverse-thermosensitive polymer for bloodless minimally invasive renal surgery.

Authors:  Sebastian Flacke; Alirezah Moinzadeh; John A Libertino; John Merhige; Jean-Marie Vogel; Kathy Lyall; Urmila Khettry; Curtis W Bakal; Peter N Madras
Journal:  J Vasc Interv Radiol       Date:  2010-03-21       Impact factor: 3.464

5.  Autoclaving of Poloxamer 407 hydrogel and its use as a drug delivery vehicle.

Authors:  Mary Catherine Beard; Leah H Cobb; Christine S Grant; Anandavalli Varadarajan; Taylor Henry; Elizabeth A Swanson; Santanu Kundu; Lauren B Priddy
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2020-08-21       Impact factor: 3.405

6.  Temporary vascular occlusion by rapid reverse phase polymer: a preliminary in vitro study of retrograde injection.

Authors:  Einar Dregelid
Journal:  Int J Biomater       Date:  2012-07-25

7.  Effects of temporary vascular occluder poloxamer 407 gel on the endothelium.

Authors:  Arif Gucu; Ilkin Cavusoglu; Onder Bozkurt; Cuneyt Eris; Faruk Toktas; Tugrul Goncu; Ahmet Ozyazicioglu
Journal:  J Cardiothorac Surg       Date:  2013-01-22       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.